文献速递淋巴瘤

低剂量放疗(4 Gy)联合或不联合化疗对复发难治套细胞淋巴瘤高度有效

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2019-01-01

研究评估低剂量放疗(4 Gy)联合化疗在复发难治套细胞淋巴瘤中的作用,2014至2018年19例患者共98个部位接受4 Gy放疗,中位随访15.4个月,完全缓解率81%,无放疗相关毒性,1年总生存率90%。

要点

  • 4 Gy低剂量放疗联合化疗在复发难治套细胞淋巴瘤中完全缓解率达81%。
  • 伊布替尼难治、既往化疗>5程或肿瘤>3 cm者完全缓解无差异。
  • 无放疗相关毒性,可安全联合化疗、多部位及重复照射。

核心结论

  • 低剂量放疗对复发难治套细胞淋巴瘤有效,可安全联合化疗、多部位及重复照射,提供持久局部控制并可能桥接后续新疗法。

研究设计与样本

  • 2014至2018年,19例复发难治套细胞淋巴瘤患者共98个部位接受4 Gy低剂量放疗,中位随访15.4个月。

主要发现

  • 98个部位中76%对持续化疗难治,76%的放疗同步联合化疗;58%患者为伊布替尼难治。
  • 放疗后中位2.7个月完全缓解率为81%,伊布替尼难治、既往化疗>5程或肿瘤>3 cm者完全缓解无差异。
  • 无放疗相关毒性;初始低剂量放疗后1年总生存率90%,末次疗程后1年无进展生存率55%。

临床怎么用

  • 低剂量放疗可安全联合化疗、多部位及重复照射,用于复发难治套细胞淋巴瘤的局部控制和桥接后续新疗法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) generally exhibits an aggressive disease course with poor outcomes. Despite inherent radiosensitivity, radiation therapy (RT) is not commonly used for MCL. This study assesses the role of low-dose RT (LDRT) with concurrent chemotherapy in relapsed, multiply refractory MCL. From 2014 through 2018, 19 patients with relapsed, refractory MCL had 98 sites treated with 4 Gy. Median follow-up from initial LDRT was 15.4 months. Patients had received a median 7 courses of chemotherapy since diagnosis, and 58% were ibrutinib-refractory. Of the 98 sites, 76% were refractory to ongoing chemotherapy, and LDRT was delivered with concurrent chemotherapy for 76%. The complete response (CR) rate was 81% at a median 2.7 months post-LDRT. There were no differences in CR despite ibrutinib-refractory disease, prior chemotherapy courses (>5), or tumor size (>3 cm). There were no RT-related toxicities. Overall survival at 1 year following initial LDRT was 90%, and 1-year progression-free survival following last course was 55%. In summary, LDRT is effective for relapsed, multiply refractory MCL, and may be safely delivered with chemotherapy, to multiple sites, and repeatedly without issue. By treating active sites of disease, LDRT can provide durable local control, help achieve remission, and potentially bridge patients to subsequent novel therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ning MS, Pinnix CC, Chapman BV, et al. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv. 2019. PMID: 31289030. doi:10.1182/bloodadvances.2019030858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。